FDA Grants Emergency Use Authorization To Regeneron’s SARS-CoV-2 Antibody Treatment
- November 23, 2020
The New York Times (11/21, Thomas, Weiland) reported the FDA granted emergency use authorization to Regeneron’s SARS-CoV-2 antibody treatment. Regeneron’s treatment “is a cocktail of two powerful antibodies that have shown promise in early studies at keeping the infection in check, reducing medical visits in patients who get the drug early in the course of their disease.” Earlier this month, the FDA granted an emergency use authorization to a similar treatment made by Eli Lilly.
The AP (11/21, Marchione) reported the FDA authorized the treatment for people who are at least 12 years old, who weigh at least 88 pounds, “and who are at high risk of severe illness from [SARS-CoV-2] because of age or certain other medical conditions.” Regeneron’s treatment “is given as a one-time treatment through an IV.”